Clinical Trial: A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age.

U.S., April 30 -- ClinicalTrials.gov registry received information related to the study (NCT07555392) titled 'A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age.' on April 17.

Brief Summary: A Seamless Phase II/III, Observer-blind, Multi-centre, Randomized Clinical Trial to Evaluate Immunogenicity and Safety of BBV87, an Inactivated Chikungunya Virus Vaccine in Healthy Subjects 12-65 Years of Age

Study Start Date: April 20

Study Type: INTERVENTIONAL

Condition: Active Immunisation for Chikungunya Virus Infection

Intervention: BIOLOGICAL: BBV87 Chikungunya vaccine

Inactivated Chikungunya Virus Vaccine (BBV87)

BIOLOGICAL: Placebo

Placebo or...